SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 136 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3177>> Hope NEW FDA will be more open for suggestions!!? << How could ascaram(o)uche-4/24/2018
3176Not clear is it JAK2 related, not related to platelets count (which actually decMiljenko Zuanic-4/24/2018
3175Therapeutic window!! Large enough that a panel of FDA-deemed experts said yes! scaram(o)uche-4/24/2018
3174Never hear so much (and so many) incompetent panels of RA "experts"! Miljenko Zuanic14/23/2018
3173Now the FDA AdCom vote. Two doses. 10-5 in favor of 2mg, and 10-5 against the tuck-4/23/2018
3172OT: ONCE benefited the most! EOMMiljenko Zuanic-4/10/2018
3171Ah, OK. Thought the big move was all avxs sentiment. Thanks!scaram(o)uche-4/10/2018
3170Seems that AAV5 ( AMT-061) has lower pre-existing mAbs titar! They are going strMiljenko Zuanic-4/9/2018
3169OT >> OT: Nice move in QURE, too! << Look at the daily chart for qscaram(o)uche-4/9/2018
3168RA.... I still do not understand the fast turnaround from the baricitinib CRLscaram(o)uche-4/9/2018
3167Indeed, strong data for JAK1 Upadacitinib. Competition for GLPG/GILD too. Two Miljenko Zuanic-4/9/2018
3166AbbVie scores a clinical win with its JAK1 inhibitor in RA. Not good news for Ituck-4/9/2018
3165>> How big is this limb we're on?? << Twig.scaram(o)uche-4/6/2018
3164Well, regards the in-house combination, ...they are main sponsor and they let KeMiljenko Zuanic-1/23/2018
3163downstream = wrong wordscaram(o)uche-1/9/2018
3162You're not the only one who's talking about a PFE-BMY hookup :- )DewDiligence_on_SI-1/9/2018
3161Indeed, P2 Epa-PD1 chombo data v PD1 mono (multiple indications) are very stronMiljenko Zuanic-1/9/2018
3160These findings are important translationally, because they suggest broader cliniscaram(o)uche-1/9/2018
3159>> At JPM, INCY was cautious on IDO1 << With all of the commentary scaram(o)uche-1/9/2018
3158At JPM, INCY was cautious on IDO1, so...PFE exiting IDO-target may (after hearinMiljenko Zuanic-1/9/2018
3157Celgene buying fedratinib for what????? PGS and friends discussing it at twittescaram(o)uche-1/7/2018
3156Thanks, we agree Indo is not an INDO-1 inhibitor. <Thus, indoximod acts as aMiljenko Zuanic-1/4/2018
3155I don't really understand the PFE decision. Based on IDO's role, it'former_pgs11/4/2018
3154I do not think that it is kynurenine level (as biomarker) that describe path forMiljenko Zuanic-1/4/2018
3153The main differentiating characteristic of the iTeos compound was its penetratiotuck11/4/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):